Experimental Pediatric Ulcerative Colitis Drug Picks Up Orphan Drug Status

Experimental Pediatric Ulcerative Colitis Drug Picks Up Orphan Drug Status
AvaxiaBiologics,Inc. recently announced that the US Food and Drug Administration (FDA) granted their lead experimental drug AVX-470 Orphan Drug Designation for the treatment of pediatric ulcerative colitis. The news comes after the company previously announced the results of their Phase 1b clinical trial for AVX-470. Ulcerative colitis (one of the two most common types of Inflammatory Bowel Disease) is characterized by inflammation of the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *